NCT04001075View on ClinicalTrials.gov

Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

September 23, 2021

Conditions
Advanced Solid Tumord
Interventions
DRUG

TJ107

Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period

Trial Locations (4)

110001

the First Affiliated Hospital of China Medical University, Shenyang

200120

Shanghai East Hospital, Shanghai

310016

Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of the Medical, Hangzhou

510655

The sixth Affiliated Hospital, Sun Yat-sen University, Guanzhou

All Listed Sponsors
lead

TJ Biopharma Co., Ltd.

INDUSTRY

NCT04001075 - Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter